{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T02:48:15Z","timestamp":1793674095146,"version":"4.5.1"},"reference-count":113,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure: European Journal of Epilepsy"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.seizure.2023.03.017","type":"journal-article","created":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T22:03:50Z","timestamp":1679609030000},"page":"121-131","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"special_numbering":"C","title":["Levetiracetam, from broad-spectrum use to precision prescription: A narrative review and expert opinion"],"prefix":"10.1016","volume":"107","author":[{"given":"Adriana","family":"Celdran de Castro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7161-6385","authenticated-orcid":false,"given":"F\u00e1bio A.","family":"Nascimento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1lvaro","family":"Beltran-Corbellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Toledano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Garcia-Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4515-0793","authenticated-orcid":false,"given":"Antonio","family":"Gil-Nagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngel","family":"Aledo-Serrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.seizure.2023.03.017_bib0001","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.649589","article-title":"Anti-seizure Medication Prescription in Adult Outpatients With Epilepsy in China, 2013-2018","volume":"12","author":"Yu","year":"2021","journal-title":"Front Neurol"},{"issue":"12","key":"10.1016\/j.seizure.2023.03.017_bib0002","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-032551","article-title":"Trends in antiepileptic drug treatment and effectiveness in clinical practice in England from 2003 to 2016: a retrospective cohort study using electronic medical records","volume":"9","author":"Powell","year":"2019","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.seizure.2023.03.017_bib0003","doi-asserted-by":"crossref","first-page":"8","DOI":"10.9740\/mhc.2015.01.008","article-title":"Pharmacokinetic characteristics of antiepileptic drugs (AEDs)","volume":"6","author":"Marvanova","year":"2016","journal-title":"Ment Health Clin"},{"issue":"3","key":"10.1016\/j.seizure.2023.03.017_bib0004","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM198507183130303","article-title":"Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures","volume":"313","author":"Mattson","year":"1985","journal-title":"N Engl J Med."},{"issue":"1","key":"10.1016\/j.seizure.2023.03.017_bib0005","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1177\/15357597211052129","article-title":"SANAD II: dear Levetiracetam, the Honeymoon Is Over","volume":"22","author":"Bermeo-Ovalle","year":"2021","journal-title":"Epilepsy Curr"},{"issue":"10282","key":"10.1016\/j.seizure.2023.03.017_bib0006","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/S0140-6736(21)00246-4","article-title":"The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial","volume":"397","author":"Marson","year":"2021","journal-title":"Lancet"},{"issue":"10282","key":"10.1016\/j.seizure.2023.03.017_bib0007","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/S0140-6736(21)00247-6","article-title":"The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial","volume":"397","author":"Marson","year":"2021","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.seizure.2023.03.017_bib0008","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1136\/jnnp-2011-300376","article-title":"KOMET: an unblinded, randomised, two parallel-group, stratified trial comparing the effectiveness of levetiracetam with controlled-release carbamazepine and extended-release sodium valproate as monotherapy in patients with newly diagnosed epilepsy","volume":"84","author":"Trinka","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.seizure.2023.03.017_bib0009","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s42494-021-00055-z","article-title":"The pharmacological treatment of epilepsy: recent advances and future perspectives","volume":"3","author":"Perucca","year":"2021","journal-title":"Acta Epileptologica"},{"issue":"9","key":"10.1016\/j.seizure.2023.03.017_bib0010","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1111\/epi.17017","article-title":"Etiology-specific response to antiseizure medication in focal epilepsy","volume":"62","author":"Doerrfuss","year":"2021","journal-title":"Epilepsia"},{"issue":"2","key":"10.1016\/j.seizure.2023.03.017_bib0011","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1136\/practneurol-2021-003217","article-title":"Challenge to levetiracetam's de facto position as generic first-line antiseizure medication","volume":"22","author":"Neligan","year":"2022","journal-title":"Pract Neurol"},{"issue":"4","key":"10.1016\/j.seizure.2023.03.017_bib0012","doi-asserted-by":"crossref","first-page":"475","DOI":"10.3390\/ph15040475","article-title":"Levetiracetam Mechanisms of Action: from Molecules to Systems","volume":"15","author":"Contreras-Garc\u00eda","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"issue":"11","key":"10.1016\/j.seizure.2023.03.017_bib0013","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1111\/ejn.12360","article-title":"Synaptic vesicle protein 2A: basic facts and role in synaptic function","volume":"38","author":"Mendoza-Torreblanca","year":"2013","journal-title":"Eur J Neurosci"},{"issue":"5","key":"10.1016\/j.seizure.2023.03.017_bib0014","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/sj.bjp.0704766","article-title":"The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents","volume":"136","author":"Rigo","year":"2002","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.seizure.2023.03.017_bib0015","article-title":"A de novo heterozygous rare variant in SV2A causes epilepsy and levetiracetam-induced drug-resistant status epilepticus","volume":"15","author":"Calame","year":"2021","journal-title":"Epilepsy Behav Rep"},{"issue":"3","key":"10.1016\/j.seizure.2023.03.017_bib0016","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0920-1211(96)00031-9","article-title":"Photosensitive epilepsy: a model to study the effects of antiepileptic drugs. Evaluation of the piracetam analogue, levetiracetam","volume":"25","author":"Kasteleijn-Nolst Trenit\u00e9","year":"1996","journal-title":"Epilepsy Res"},{"issue":"4","key":"10.1016\/j.seizure.2023.03.017_bib0017","first-page":"489","article-title":"Levetiracetam: a review of its use in epilepsy","volume":"71","author":"Lyseng-Williamson","year":"2011","journal-title":"Drugs"},{"issue":"22","key":"10.1016\/j.seizure.2023.03.017_bib0018","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1905795","article-title":"Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus","volume":"381","author":"Kapur","year":"2019","journal-title":"N Engl J Med"},{"issue":"10186","key":"10.1016\/j.seizure.2023.03.017_bib0019","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/S0140-6736(19)30724-X","article-title":"Levetiracetam versus phenytoin for second-line treatment of paediatric convulsive status epilepticus (EcLiPSE): a multicentre, open-label, randomised trial","volume":"393","author":"Lyttle","year":"2019","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.seizure.2023.03.017_bib0020","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1097\/00002826-198812000-00006","article-title":"Piracetam in the treatment of different types of myoclonus","volume":"11","author":"Obeso","year":"1988","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.seizure.2023.03.017_bib0021","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.seizure.2019.04.021","article-title":"Effect of brivaracetam on the anger levels of epilepsy patients. A prospective open-labelled controlled study","volume":"69","author":"Toledo","year":"2019","journal-title":"Seizure"},{"issue":"46","key":"10.1016\/j.seizure.2023.03.017_bib0022","doi-asserted-by":"crossref","first-page":"3800","DOI":"10.1093\/eurheartj\/ehz657","article-title":"Levetiracetam and non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and epilepsy: a reasonable combination","volume":"40","author":"Von Oertzen","year":"2019","journal-title":"Eur Heart J"},{"issue":"9","key":"10.1016\/j.seizure.2023.03.017_bib0023","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1212\/01.WNL.0000091865.46063.67","article-title":"Discontinuation of levetiracetam because of behavioral side effects: a case-control study","volume":"61","author":"White","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2023.03.017_bib0024","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.yebeh.2017.08.039","article-title":"Psychiatric and behavioral side effects of antiepileptic drugs in adults with epilepsy","volume":"76","author":"Chen","year":"2017","journal-title":"Epilepsy Behav"},{"issue":"2","key":"10.1016\/j.seizure.2023.03.017_bib0025","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1212\/WNL.55.2.236","article-title":"Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial","volume":"55","author":"Cereghino","year":"2000","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.seizure.2023.03.017_bib0026","first-page":"1179","article-title":"Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures","volume":"41","author":"Shorvon","year":"2000","journal-title":"Eur Levetiracetam Study Group. Epilepsia."},{"key":"10.1016\/j.seizure.2023.03.017_bib0027","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1111\/j.1528-1157.2000.tb04605.x","article-title":"Efficacy and tolerability of levetiracetam 3000mg in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy","volume":"41","author":"Ben-Menachem","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2023.03.017_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2020.107644","article-title":"Differences in levetiracetam and perampanel treatment-related irritability in patients with epilepsy","volume":"116","author":"Hasegawa","year":"2021","journal-title":"Epilepsy Behav"},{"issue":"6","key":"10.1016\/j.seizure.2023.03.017_bib0029","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1111\/epi.17228","article-title":"A pharmacogenomic assessment of psychiatric adverse drug reactions to levetiracetam","volume":"63","author":"Campbell","year":"2022","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.seizure.2023.03.017_bib0030","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1528-1167.2012.03603.x","article-title":"Genetic variation in dopaminergic activity is associated with the risk for psychiatric side effects of levetiracetam","volume":"54","author":"Helmstaedter","year":"2013","journal-title":"Epilepsia"},{"issue":"4","key":"10.1016\/j.seizure.2023.03.017_bib0031","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1001\/jamaneurol.2018.4561","article-title":"Prediction Tools for Psychiatric Adverse Effects After Levetiracetam Prescription","volume":"76","author":"Josephson","year":"2019","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.seizure.2023.03.017_bib0032","unstructured":"U.S. Food and Drug Administration (FDA). FDA-Approved Drugs. Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/021035s104,021505s044lbl.pdf (Retrieved: July 2022)."},{"key":"10.1016\/j.seizure.2023.03.017_bib0033","unstructured":"European Medicines Agency (EMA). Keppra. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/keppra#authorisation-details-section (Retrieved: July 2022)."},{"key":"10.1016\/j.seizure.2023.03.017_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2022.108666","article-title":"Trends in antiseizure medication prescription patterns among all adults, women, and older adults with epilepsy: a German longitudinal analysis from 2008 to 2020","volume":"130","author":"Hochbaum","year":"2022","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2023.03.017_bib0035","unstructured":"European Medicines Agency, New measures to avoid valproate exposure in pregnancy endorsed, 2018, EMA\/375438\/2018. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/referral\/valproate-article-31-referral-new-measures-avoid-valproate-exposure-pregnancy-endorsed_en-0.pdf."},{"issue":"8","key":"10.1016\/j.seizure.2023.03.017_bib0036","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s40263-018-0544-2","article-title":"Use of emergency medication in adult patients with epilepsy: a multicentre cohort study from Germany","volume":"32","author":"Kadel","year":"2018","journal-title":"CNS Drugs"},{"key":"10.1016\/j.seizure.2023.03.017_bib0037","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2021.106812","article-title":"Antiseizure medication for brain metastasis-related epilepsy: findings of optimal choice from a retrospective cohort","volume":"178","author":"S\u00e1nchez-Villalobos","year":"2021","journal-title":"Epilepsy Res"},{"issue":"1","key":"10.1016\/j.seizure.2023.03.017_bib0038","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1007\/s12028-021-01296-z","article-title":"Levetiracetam for Seizure Prophylaxis in Neurocritical Care: a Systematic Review and Meta-analysis","volume":"36","author":"Fang","year":"2022","journal-title":"Neurocrit Care"},{"key":"10.1016\/j.seizure.2023.03.017_bib0039","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.pediatrneurol.2017.06.011","article-title":"Initial Treatment for Nonsyndromic Early-Life Epilepsy: an Unexpected Consensus","volume":"75","author":"Shellhaas","year":"2017","journal-title":"Pediatr Neurol"},{"issue":"18","key":"10.1016\/j.seizure.2023.03.017_bib0040","doi-asserted-by":"crossref","first-page":"e2509","DOI":"10.1212\/WNL.0000000000010874","article-title":"Pharmacologic treatment and SUDEP risk: a nationwide, population-based, case-control study","volume":"95","author":"Sveinsson","year":"2020","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.seizure.2023.03.017_bib0041","article-title":"Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data","volume":"4","author":"Nevitt","year":"2022","journal-title":"Cochrane Database Syst Rev."},{"key":"10.1016\/j.seizure.2023.03.017_bib0042","unstructured":"National Institute for Health and Care Excellence (NICE) guidelines, Epilepsies in children, young people and adults, NICE guideline 217, Available at: https:\/\/www.nice.org.uk\/guidance\/ng217."},{"issue":"3","key":"10.1016\/j.seizure.2023.03.017_bib0043","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.yebeh.2007.06.005","article-title":"Adjunctive therapy of uncontrolled partial seizures with levetiracetam in Australian patients","volume":"11","author":"Somerville","year":"2007","journal-title":"Epilepsy Behav"},{"issue":"6","key":"10.1016\/j.seizure.2023.03.017_bib0044","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1212\/01.wnl.0000252941.50833.4a","article-title":"Levetiracetam Monotherapy Study Group. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy","volume":"68","author":"Brodie","year":"2007","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.seizure.2023.03.017_bib0045","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1212\/01.wnl.0000297512.18364.40","article-title":"Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures","volume":"70","author":"Noachtar","year":"2008","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.seizure.2023.03.017_bib0046","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/j.1528-1167.2010.02976.x","article-title":"A multicenter, randomized, placebo-controlled trial of levetiracetam in children and adolescents with newly diagnosed absence epilepsy","volume":"52","author":"Fattore","year":"2011","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.seizure.2023.03.017_bib0047","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/epi.12926","article-title":"A randomized, double-blind comparison of antiepileptic drug treatment in the elderly with new-onset focal epilepsy","volume":"56","author":"Werhahn","year":"2015","journal-title":"Epilepsia"},{"issue":"10186","key":"10.1016\/j.seizure.2023.03.017_bib0048","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1016\/S0140-6736(19)30722-6","article-title":"Levetiracetam versus phenytoin for second-line treatment of convulsive status epilepticus in children (ConSEPT): an open-label, multicentre, randomised controlled trial","volume":"393","author":"Dalziel","year":"2019","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.seizure.2023.03.017_bib0049","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1111\/cns.13840","article-title":"Efficacy comparison of oxcarbazepine and levetiracetam monotherapy among patients with newly diagnosed focal epilepsy in China: a multicenter, open-label, randomized study","volume":"28","author":"Zhu","year":"2022","journal-title":"CNS Neurosci Ther"},{"key":"10.1016\/j.seizure.2023.03.017_bib0050","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.seizure.2020.12.005","article-title":"Alternatives to valproate in girls and women of childbearing potential with Idiopathic Generalized Epilepsies: state of the art and guidance for the clinician proposed by the Epilepsy and Gender Commission of the Italian League Against Epilepsy (LICE)","volume":"85","author":"Mostacci","year":"2021","journal-title":"Seizure"},{"issue":"3","key":"10.1016\/j.seizure.2023.03.017_bib0051","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.seizure.2005.12.004","article-title":"Levetiracetam in patients with generalized epilepsy and myoclonic seizures: an open label study","volume":"15","author":"Labate","year":"2006","journal-title":"Seizure"},{"issue":"6","key":"10.1016\/j.seizure.2023.03.017_bib0052","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1111\/j.0013-9580.2004.56902.x","article-title":"Antimyoclonic effect of levetiracetam in 13 patients with Unverricht-Lundborg disease: clinical observations","volume":"45","author":"Magaudda","year":"2004","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.seizure.2023.03.017_bib0053","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1517\/17425255.2012.644535","article-title":"Mitochondrial toxicity of antiepileptic drugs and their tolerability in mitochondrial disorders","volume":"8","author":"Finsterer","year":"2012","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"1","key":"10.1016\/j.seizure.2023.03.017_bib0054","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12887-015-0330-y","article-title":"Paradoxical exacerbation of myoclonic-astatic seizures by levetiracetam in myoclonic astatic epilepsy","volume":"15","author":"Makke","year":"2015","journal-title":"BMC Pediatr"},{"issue":"4","key":"10.1016\/j.seizure.2023.03.017_bib0055","doi-asserted-by":"crossref","first-page":"e64","DOI":"10.1111\/epi.13702","article-title":"Resistance to valproic acid as predictor of treatment resistance in genetic generalized epilepsies","volume":"58","author":"Gesche","year":"2017","journal-title":"Epilepsia"},{"issue":"10","key":"10.1016\/j.seizure.2023.03.017_bib0056","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1007\/s40263-020-00761-1","article-title":"Rapidity of CNS effect on photoparoxysmal response for Brivaracetam vs. levetiracetam: a randomized, double-blind, crossover trial in photosensitive epilepsy patients","volume":"34","author":"Reed","year":"2020","journal-title":"CNS Drugs"},{"issue":"4","key":"10.1016\/j.seizure.2023.03.017_bib0057","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/epi.17175","article-title":"Visually sensitive seizures: an updated review by the Epilepsy Foundation","volume":"63","author":"Fisher","year":"2022","journal-title":"Epilepsia"},{"issue":"6","key":"10.1016\/j.seizure.2023.03.017_bib0058","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1111\/epi.17241","article-title":"International League Against Epilepsy classification and definition of epilepsy syndromes with onset in childhood: position paper by the ILAE task force on nosology and definitions","volume":"63","author":"Specchio","year":"2022","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2023.03.017_bib0059","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.seizure.2021.05.005","article-title":"Uncommon epileptic syndromes in children: a review","volume":"90","author":"de la Jara","year":"2021","journal-title":"Seizure"},{"issue":"1\u20132","key":"10.1016\/j.seizure.2023.03.017_bib0060","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jns.2014.03.051","article-title":"Levetiracetam as alternative treatment in Jeavons syndrome","volume":"341","author":"Parissis","year":"2014","journal-title":"J Neurol Sci"},{"issue":"3","key":"10.1016\/j.seizure.2023.03.017_bib0061","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/j.1528-1167.2007.01524.x","article-title":"A pilot trial of levetiracetam in eyelid myoclonia with absences (Jeavons syndrome)","volume":"49","author":"Striano","year":"2008","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2023.03.017_bib0062","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.eplepsyres.2018.03.002","article-title":"Clinical and electrographic features of sunflower syndrome","volume":"142","author":"Baumer","year":"2018","journal-title":"Epilepsy Res"},{"issue":"1","key":"10.1016\/j.seizure.2023.03.017_bib0063","doi-asserted-by":"crossref","first-page":"6254","DOI":"10.1038\/s41598-018-24644-0","article-title":"Genetic (idiopathic) epilepsy with photosensitive seizures includes features of both focal and generalized seizures","volume":"8","author":"Xue","year":"2018","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.seizure.2023.03.017_bib0064","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1684\/epd.2018.0994","article-title":"Genetic (idiopathic) generalized epilepsy with occipital semiology","volume":"20","author":"G\u00f3mez-Porro","year":"2018","journal-title":"Epileptic Disord"},{"key":"10.1016\/j.seizure.2023.03.017_bib0065","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.seizure.2020.06.007","article-title":"Antiseizure medication withdrawal in seizure-free patients with PCDH19-related epilepsy: a multinational cohort survey","volume":"80","author":"Aledo-Serrano","year":"2020","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2023.03.017_bib0066","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ejpn.2019.12.020","article-title":"Levetiracetam efficacy in PCDH19 Girls Clustering Epilepsy","volume":"24","author":"Sadleir","year":"2020","journal-title":"Eur J Paediatr Neurol"},{"issue":"10","key":"10.1016\/j.seizure.2023.03.017_bib0067","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1111\/epi.13107","article-title":"Epileptic encephalopathies: optimizing seizure control and developmental outcome","volume":"56","author":"Jehi","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2023.03.017_bib0068","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.777115","article-title":"Epilepsy Genetics and Precision Medicine in Adults: a New Landscape for Developmental and Epileptic Encephalopathies","volume":"13","author":"Beltr\u00e1n-Corbellini","year":"2022","journal-title":"Front Neurol"},{"issue":"Pt A","key":"10.1016\/j.seizure.2023.03.017_bib0069","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.yebeh.2019.06.021","article-title":"Seizure management and prescription patterns of anticonvulsants in Dravet syndrome: a multicenter cohort study from Germany and review of literature","volume":"98","author":"Schubert-Bast","year":"2019","journal-title":"Epilepsy Behav"},{"issue":"1","key":"10.1016\/j.seizure.2023.03.017_bib0070","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.braindev.2015.07.002","article-title":"Dramatic effect of levetiracetam in early-onset epileptic encephalopathy due to STXBP1 mutation","volume":"38","author":"Dilena","year":"2016","journal-title":"Brain Dev"},{"key":"10.1016\/j.seizure.2023.03.017_bib0071","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.seizure.2021.12.006","article-title":"Efficacy of levetiracetam in STXBP1 encephalopathy with different phenotypic and genetic spectra","volume":"95","author":"Wang","year":"2022","journal-title":"Seizure"},{"issue":"13","key":"10.1016\/j.seizure.2023.03.017_bib0072","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.3390\/jcm10132776","article-title":"Epilepsy in Down Syndrome: a Highly Prevalent Comorbidity","volume":"10","author":"Altuna","year":"2021","journal-title":"J Clin Med"},{"issue":"2","key":"10.1016\/j.seizure.2023.03.017_bib0073","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.nrl.2014.12.008","article-title":"Myoclonic epilepsy in Down syndrome and Alzheimer disease","volume":"32","author":"Aller-Alvarez","year":"2017","journal-title":"Neurologia"},{"issue":"1","key":"10.1016\/j.seizure.2023.03.017_bib0074","doi-asserted-by":"crossref","first-page":"27","DOI":"10.14581\/jer.19003","article-title":"Epilepsy in the Elderly: treatment and Consideration of Comorbid Diseases","volume":"9","author":"Lee","year":"2019","journal-title":"J Epilepsy Res"},{"issue":"1","key":"10.1016\/j.seizure.2023.03.017_bib0075","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1177\/1533317508319433","article-title":"Treatment and management of epilepsy in the elderly demented patient","volume":"25","author":"Jenssen","year":"2010","journal-title":"Am J Alzheimers Dis Other Demen"},{"issue":"12","key":"10.1016\/j.seizure.2023.03.017_bib0076","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/nrn.2016.141","article-title":"Network abnormalities and interneuron dysfunction in Alzheimer disease","volume":"17","author":"Palop","year":"2016","journal-title":"Nat Rev Neurosci"},{"issue":"6","key":"10.1016\/j.seizure.2023.03.017_bib0077","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/ana.24794","article-title":"Incidence and impact of subclinical epileptiform activity in Alzheimer's disease","volume":"80","author":"Vossel","year":"2016","journal-title":"Ann Neurol"},{"issue":"42","key":"10.1016\/j.seizure.2023.03.017_bib0078","doi-asserted-by":"crossref","first-page":"E2895","DOI":"10.1073\/pnas.1121081109","article-title":"Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model","volume":"109","author":"Sanchez","year":"2012","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"11","key":"10.1016\/j.seizure.2023.03.017_bib0079","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1001\/jamaneurol.2021.3310","article-title":"Effect of levetiracetam on cognition in patients with alzheimer disease with and without epileptiform activity: a randomized clinical trial","volume":"78","author":"Vossel","year":"2021","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.1016\/j.seizure.2023.03.017_bib0080","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1186\/s13063-021-05404-4","article-title":"An Investigation of Levetiracetam in Alzheimer's Disease (ILiAD): a double-blind, placebo-controlled, randomised crossover proof of concept study","volume":"22","author":"Sen","year":"2021","journal-title":"Trials"},{"issue":"11","key":"10.1016\/j.seizure.2023.03.017_bib0081","article-title":"Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child","volume":"11","author":"Weston","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"10.1016\/j.seizure.2023.03.017_bib0082","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/S1474-4422(18)30107-8","article-title":"Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry","volume":"17","author":"Tomson","year":"2018","journal-title":"Lancet Neurol"},{"issue":"6","key":"10.1016\/j.seizure.2023.03.017_bib0083","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/epi.15968","article-title":"Behavioral problems in children of mothers with epilepsy prenatally exposed to valproate, carbamazepine, lamotrigine, or levetiracetam monotherapy","volume":"60","author":"Huber-Mollema","year":"2019","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2023.03.017_bib0084","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.seizure.2022.03.017","article-title":"Concentrations of antiseizure medications in breast milk of lactating women with epilepsy: a systematic review with qualitative synthesis","volume":"98","author":"Shawahna","year":"2022","journal-title":"Seizure"},{"issue":"4","key":"10.1016\/j.seizure.2023.03.017_bib0085","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1001\/jamaneurol.2021.5487","article-title":"Antiseizure medication concentrations during pregnancy: results from the maternal outcomes and neurodevelopmental effects of antiepileptic drugs (MONEAD) study","volume":"79","author":"Pennell","year":"2022","journal-title":"JAMA Neurol"},{"issue":"2","key":"10.1016\/j.seizure.2023.03.017_bib0086","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1177\/0883073818811511","article-title":"Clinical Use and Efficacy of Levetiracetam for Absence Epilepsies","volume":"34","author":"Nolan","year":"2019","journal-title":"J Child Neurol"},{"issue":"8","key":"10.1016\/j.seizure.2023.03.017_bib0087","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1111\/epi.14476","article-title":"Use of brivaracetam in genetic generalized epilepsies and for acute, intravenous treatment of absence status epilepticus","volume":"59","author":"Strzelczyk","year":"2018","journal-title":"Epilepsia"},{"issue":"8","key":"10.1016\/j.seizure.2023.03.017_bib0088","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1093\/brain\/awaa072","article-title":"Clinical and experimental insight into pathophysiology, comorbidity and therapy of absence seizures","volume":"143","author":"Crunelli","year":"2020","journal-title":"Brain"},{"key":"10.1016\/j.seizure.2023.03.017_bib0089","doi-asserted-by":"crossref","DOI":"10.1177\/17562864211050027","article-title":"Response to antiseizure medications in epileptic patients with malformation of cortical development","volume":"14","author":"Chen","year":"2021","journal-title":"Ther Adv Neurol Disord"},{"issue":"6","key":"10.1016\/j.seizure.2023.03.017_bib0090","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1097\/WNF.0000000000000304","article-title":"Levetiracetam-Induced Seizure Aggravation in Patients With Focal Cortical Dysplasia","volume":"41","author":"Cvetkovska","year":"2018","journal-title":"Clin Neuropharmacol"},{"issue":"6","key":"10.1016\/j.seizure.2023.03.017_bib0091","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1111\/j.1528-1167.2008.01955.x","article-title":"Expression patterns of synaptic vesicle protein 2A in focal cortical dysplasia and TSC-cortical tubers","volume":"50","author":"Toering","year":"2009","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.seizure.2023.03.017_bib0092","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/j.1528-1167.2008.01727.x","article-title":"Decreased expression of synaptic vesicle protein 2A, the binding site for levetiracetam, during epileptogenesis and chronic epilepsy","volume":"50","author":"van Vliet","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2023.03.017_bib0093","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3389\/fneur.2013.00099","article-title":"Neurobehavioral effects of levetiracetam in brain tumor related epilepsy","volume":"4","author":"Bernett","year":"2013","journal-title":"Front Neurol."},{"issue":"6","key":"10.1016\/j.seizure.2023.03.017_bib0094","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1212\/WNL.0b013e318228c110","article-title":"Synaptic vesicle protein 2A predicts response to levetiracetam in patients with glioma","volume":"77","author":"de Groot","year":"2011","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.seizure.2023.03.017_bib0095","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1007\/s00415-019-09410-0","article-title":"Synaptic vesicle protein 2A tumoral expression predicts levetiracetam adverse events","volume":"266","author":"Romoli","year":"2019","journal-title":"J Neurol"},{"issue":"5","key":"10.1016\/j.seizure.2023.03.017_bib0096","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1007\/s00415-017-8463-6","article-title":"Brain tumor location influences the onset of acute psychiatric adverse events of levetiracetam therapy: an observational study","volume":"264","author":"Belcastro","year":"2017","journal-title":"J Neurol"},{"issue":"1","key":"10.1016\/j.seizure.2023.03.017_bib0097","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1136\/archdischild-2013-304211","article-title":"Antiepileptic drug treatment of rolandic epilepsy and Panayiotopoulos syndrome: clinical practice survey and clinical trial feasibility","volume":"100","author":"Mellish","year":"2015","journal-title":"Arch Dis Child"},{"issue":"3","key":"10.1016\/j.seizure.2023.03.017_bib0098","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.yebeh.2010.07.018","article-title":"Benign epilepsy of childhood with centrotemporal spikes (BECTS): to treat or not to treat, that is the question","volume":"19","author":"Hughes","year":"2010","journal-title":"Epilepsy Behav"},{"issue":"Pt A","key":"10.1016\/j.seizure.2023.03.017_bib0099","article-title":"Clinical and electrophysiological predictors of behavioral disorders in patients with benign childhood epilepsy with centrotemporal spikes","volume":"121","author":"\u00d6zgen","year":"2021","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2023.03.017_bib0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2019.106261","article-title":"A multi-disciplinary clinic for SCN8A-related epilepsy","volume":"159","author":"Schreiber","year":"2020","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.seizure.2023.03.017_bib0101","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.826211","article-title":"Synaptopathies in developmental and epileptic encephalopathies: a focus on pre-synaptic dysfunction","volume":"13","author":"Spoto","year":"2022","journal-title":"Front Neurol."},{"issue":"5","key":"10.1016\/j.seizure.2023.03.017_bib0102","doi-asserted-by":"crossref","DOI":"10.1212\/NXG.0000000000200020","article-title":"Efficacy, tolerability, and retention of antiseizure medications in PRRT2-Associated Infantile epilepsy","volume":"8","author":"D\u00f6ring","year":"2022","journal-title":"Neurol Genet"},{"key":"10.1016\/j.seizure.2023.03.017_bib0103","first-page":"443","article-title":"Developmental and epileptic encephalopathies after negative or inconclusive genetic testing: what is next?","volume":"5","author":"Aledo-Serrano","year":"2021","journal-title":"J Transl Genet Genom"},{"issue":"10231","key":"10.1016\/j.seizure.2023.03.017_bib0104","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/S0140-6736(20)30611-5","article-title":"Efficacy of levetiracetam, fosphenytoin, and valproate for established status epilepticus by age group (ESETT): a double-blind, responsive-adaptive, randomised controlled trial","volume":"395","author":"Chamberlain","year":"2020","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.seizure.2023.03.017_bib0105","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s40263-017-0424-1","article-title":"Newer antiepileptic drugs in status epilepticus: prescription trends and outcomes in comparison with traditional agents","volume":"31","author":"Beuchat","year":"2017","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1016\/j.seizure.2023.03.017_bib0106","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1227\/NEU.0000000000001432","article-title":"Guidelines for the management of severe traumatic brain injury, Fourth Edition","volume":"80","author":"Carney","year":"2017","journal-title":"Neurosurgery."},{"issue":"7","key":"10.1016\/j.seizure.2023.03.017_bib0107","doi-asserted-by":"crossref","first-page":"e282","DOI":"10.1161\/STR.0000000000000407","article-title":"2022 guideline for the management of patients with spontaneous intracerebral hemorrhage: a guideline from the American Heart Association\/American Stroke Association","volume":"53","author":"Greenberg","year":"2022","journal-title":"Stroke"},{"issue":"3","key":"10.1016\/j.seizure.2023.03.017_bib0108","doi-asserted-by":"crossref","first-page":"E195","DOI":"10.1093\/neuros\/nyy545","article-title":"Congress of neurological surgeons systematic review and evidence-based guidelines on the role of prophylactic anticonvulsants in the treatment of adults with metastatic brain tumors","volume":"84","author":"Chen","year":"2019","journal-title":"Neurosurgery"},{"issue":"6","key":"10.1016\/j.seizure.2023.03.017_bib0109","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1161\/STR.0b013e3182587839","article-title":"Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American Heart Association\/american Stroke Association","volume":"43","author":"Connolly","year":"2012","journal-title":"Stroke"},{"issue":"2","key":"10.1016\/j.seizure.2023.03.017_bib0110","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1177\/2396987317705536","article-title":"European Stroke Organisation guidelines for the management of post-stroke seizures and epilepsy","volume":"2","author":"Holtkamp","year":"2017","journal-title":"Eur Stroke J"},{"issue":"10","key":"10.1016\/j.seizure.2023.03.017_bib0111","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1592\/phco.31.10.934","article-title":"Steady-state pharmacokinetics of intravenous levetiracetam in neurocritical care patients","volume":"31","author":"Spencer","year":"2011","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.seizure.2023.03.017_bib0112","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.seizure.2019.02.004","article-title":"Cerebrovascular disease burden in late-onset non-lesional focal epilepsy","volume":"66","author":"Abraira","year":"2019","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2023.03.017_bib0113","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.seizure.2022.07.003","article-title":"Efficacy and safety of antiseizure medication in post-stroke epilepsy","volume":"100","author":"Winter","year":"2022","journal-title":"Seizure"}],"container-title":["Seizure: European Journal of Epilepsy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131123000766?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131123000766?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T02:04:31Z","timestamp":1761012271000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131123000766"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":113,"alternative-id":["S1059131123000766"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2023.03.017","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Levetiracetam, from broad-spectrum use to precision prescription: A narrative review and expert opinion","name":"articletitle","label":"Article Title"},{"value":"Seizure: European Journal of Epilepsy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2023.03.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 British Epilepsy Association. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}